Medication info

Ibandronate Sodium Injection

Prescription medicationInjectionsIntravenous injection
Ingredient · strength
Ibandronate Sodium Monohydrate›3.375mg / 1 prefilled syringe
Manufacturer / importer
Kwangdong Pharmaceutical Co., Ltd.
Appearance
An injection in a colorless, transparent solution contained in a colorless, transparent glass prefilled syringe with a single-use injection needle attached.
Packaging
3ml x 1 vial
Approval status
Active

MFDS item code 201306429 · Approved 2013.03.22 · Insurance code 641807081

Summary

Main use
Treatment of osteoporosis in postmenopausal women
Who receives it
Adults · Children
Adult administration
Administer 3mg by intravenous injection over 15 - 30 seconds once every 3 months. Patients should take calcium and vitamin D supplements as an adjunct. If a dose is missed on the scheduled dosing date, administer the injection as soon as possible and continue regular dosing at 3-month intervals from then on. Patients with hepatic impairment No dosage adjustment is necessary. Patients with renal impairment No dosage adjustment is necessary for patients with mild or moderate renal impairment whose serum creatinine is ≤ 200 µmol/L (2.3mg/dL) or whose creatinine clearance is ≥ 30ml/min. Administration of this medicine is not recommended for patients whose serum creatinine is > 200 µmol/L (2.3mg/dL) or whose creatinine clearance is < 30ml/min because clinical experience is insufficient. Older adults No dosage adjustment is necessary.
Child administration
Efficacy and safety in children aged 18 years or younger have not been studied.

Ingredients

Manufacturer
Kwangdong Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of osteoporosis in postmenopausal women

  • Osteoporosis
View approved original text

Used to treat osteoporosis that tends to occur in postmenopausal women. This medication helps increase bone density and reduce the risk of fractures. It helps maintain healthy bones by preventing bone loss due to menopause. Therefore, it is used for the treatment of osteoporosis in postmenopausal women.

How it is given

Adult administration

Administer 3mg by intravenous injection over 15 - 30 seconds once every 3 months. Patients should take calcium and vitamin D supplements as an adjunct. If a dose is missed on the scheduled dosing date, administer the injection as soon as possible and continue regular dosing at 3-month intervals from then on. Patients with hepatic impairment No dosage adjustment is necessary. Patients with renal impairment No dosage adjustment is necessary for patients with mild or moderate renal impairment whose serum creatinine is ≤ 200 µmol/L (2.3mg/dL) or whose creatinine clearance is ≥ 30ml/min. Administration of this medicine is not recommended for patients whose serum creatinine is > 200 µmol/L (2.3mg/dL) or whose creatinine clearance is < 30ml/min because clinical experience is insufficient. Older adults No dosage adjustment is necessary.

Child administration

Efficacy and safety in children aged 18 years or younger have not been studied.

Precautions

This medication must be administered strictly by intravenous injection; care must be taken to avoid injecting incorrectly around arteries or veins, as this may cause tissue damage. Do not use in individuals with an allergy to this drug or its components, or those with untreated hypocalcemia. Adverse reactions may occur during treatment, primarily gastrointestinal disturbances, musculoskeletal pain, fatigue, headache, skin rash, etc. Upon initial administration, flu-like symptoms such as joint pain, muscle pain, fever, and chills may occur temporarily; however, they are generally mild and resolve without treatment. This medication may temporarily lower serum calcium levels, so calcium levels should be maintained within normal ranges before administration, and it is important to take sufficient calcium and vitamin D. Patients with poor oral hygiene or those undergoing cancer treatment may have an increased risk of osteonecrosis of the jaw, hence dental examination and preventive treatment are needed before administration. It is advisable to avoid excessive dental treatment during administration; if osteonecrosis of the jaw occurs, professional consultation is necessary as the condition may worsen. Additionally, long-term use of this medication may lead to atypical fractures in the femur or other bones, so if pain occurs in the thigh or groin, notify a doctor immediately. This medication is excreted by the kidneys, therefore patients with impaired kidney function should undergo regular examinations, and renal and liver function should be closely monitored in case of overdose. Women who are pregnant or breastfeeding should not use this medication as its safety has not been established. The safety and efficacy in children and adolescents under 18 years of age have not been confirmed. This medication should not be mixed with calcium-containing solutions or other intravenous drugs, and needles and syringes should not be reused and must be disposed of safely. Serious allergic reactions such as anaphylaxis may occur during the administration of this medication, so if any adverse symptoms appear, discontinue administration immediately and seek appropriate treatment.

Side effects

Gastritis, diarrhea, abdominal pain, indigestion, nausea, constipation, musculoskeletal pain, joint pain, muscle pain, influenza-like illness, fatigue, headache, rash, bone pain, weakness, injection site reaction, phlebitis, thrombophlebitis, hypersensitivity reaction, angioedema, facial swelling, edema, urticaria, osteonecrosis of the jaw and external auditory canal, uveitis, episcleritis, scleritis, anaphylactic reaction, shock, exacerbation of asthma, Stevens-Johnson syndrome, erythema multiforme, bullous dermatitis, atypical electronic lower extremity fracture, intertrochanteric femoral fracture, dizziness, optic atrophy, lower motor neuron lesion, tremors, unspecified gastrointestinal disease, benign gastrointestinal neoplasm, dental pain, hyperventilation, cough, shortness of breath, laryngitis, vaginitis, menopausal symptoms, insomnia, anxiety, tinnitus, hearing loss, hypothyroidism, lipoma, ocular hemorrhage, heart failure, urinary disorders, hematuria, skin exfoliation, multiple organ failure, death, sensory impairment, acute renal failure

Not everyone experiences these, and they can vary from person to person.

Storage

Store this medication in a sealed container to avoid exposure to air. It is advisable to maintain room temperature between 1 to 30 degrees Celsius. This storage will help preserve the efficacy of the medication for a longer period.

Appearance and packaging

Appearance

An injection in a colorless, transparent solution contained in a colorless, transparent glass prefilled syringe with a single-use injection needle attached.

Package unit

3ml x 1 vial

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.